» Articles » PMID: 32598517

Downregulation of MiRNA-126-3p is Associated with Progression of and Poor Prognosis for Lung Squamous Cell Carcinoma

Abstract

Lung squamous cell carcinoma (LUSC) is the main pathological type of pulmonary malignant tumors; at present, less than 10% of patients with advanced metastatic LUSC live for more than 5 years. We previously reported that low expression of miRNA-126-3p is associated with the occurrence and progression of lung adenocarcinoma (LUAD). Here, we examined expression of miRNA-126-3p in 23 samples from patients with LUSCs and 23 normal control specimens by quantitative real-time PCR (RT-qPCR). Associations between miRNA-126-3p expression and clinical features were studied from materials derived from Gene Expression Omnibus (GEO) chips and The Cancer Genome Atlas (TCGA) database. Twelve online platforms were used to identify candidate target genes of miRNA-126-3p. Further analyses of the Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene Ontology (GO), and protein-protein interaction (PPI) network were performed on the target genes. GEO microarray analysis, TCGA data mining, RT-qPCR, and integration analysis consistently reported low expression of miRNA-126-3p in LUSC. A total of 42 genes were identified as potential target genes of miRNA-126-3p from online platforms, GEO microarrays, and the TCGA database. GO and KEGG analyses demonstrated that the target genes are involved in several biological processes that promote the progression of LUSC. SOX2, E2F2, and E2F3 were selected as hub genes from the PPI network for further analysis. In summary, our results suggest that the low expression of miRNA-126-3p may play a role in promoting the development of LUSC and miRNA-126-3p may be a biomarker for LUSC early diagnosis and prognosis.

Citing Articles

Expression Profile of Thymidine Kinase Genes in Cervical Squamous Cell Carcinoma Confirmed by Various Detection Methods.

Liang C, Pang Y, Chen M, Hong L, Huang S, Guan C World J Oncol. 2025; 16(1):30-50.

PMID: 39850524 PMC: 11750753. DOI: 10.14740/wjon1962.


Non-coding RNAs in lung cancer: molecular mechanisms and clinical applications.

Liu Y, Ding W, Wang J, Ao X, Xue J Front Oncol. 2023; 13:1256537.

PMID: 37746261 PMC: 10514911. DOI: 10.3389/fonc.2023.1256537.


Reductions in extracellular vesicle-associated microRNA-126 levels in coronary blood after acute myocardial infarction: A retrospective study.

Yuan Y, Ma Y, Aili Z, Nijiati M Front Cardiovasc Med. 2022; 9:1046839.

PMID: 36523365 PMC: 9744946. DOI: 10.3389/fcvm.2022.1046839.


miR-126 Decreases Proliferation and Mammosphere Formation of MCF-7 and Predicts Prognosis of ER+ Breast Cancer.

Msheik Z, Nassar F, Chamandi G, Itani A, Gadaleta E, Chalala C Diagnostics (Basel). 2022; 12(3).

PMID: 35328298 PMC: 8946945. DOI: 10.3390/diagnostics12030745.


Salidroside suppresses the activation of nasopharyngeal carcinoma cells via targeting miR-4262/GRP78 axis.

Liu S, Li Y, Li Z Cell Cycle. 2022; 21(7):720-729.

PMID: 35220889 PMC: 8973335. DOI: 10.1080/15384101.2021.2019976.


References
1.
Xu J, Gu Y, Lewis D, Cooper D, McCathran C, Wang Y . Downregulation of vitamin D receptor and miR-126-3p expression contributes to increased endothelial inflammatory response in preeclampsia. Am J Reprod Immunol. 2019; 82(4):e13172. DOI: 10.1111/aji.13172. View

2.
Wang Z, Lu B, Sun L, Yan X, Xu J . Identification of candidate genes or microRNAs associated with the lymph node metastasis of SCLC. Cancer Cell Int. 2018; 18:161. PMC: 6194557. DOI: 10.1186/s12935-018-0653-5. View

3.
Vosa U, Vooder T, Kolde R, Vilo J, Metspalu A, Annilo T . Meta-analysis of microRNA expression in lung cancer. Int J Cancer. 2012; 132(12):2884-93. DOI: 10.1002/ijc.27981. View

4.
Han R, Chen X, Li Y, Zhang S, Li R, Lu L . MicroRNA-34a suppresses aggressiveness of hepatocellular carcinoma by modulating , and Caspase-3. Cancer Manag Res. 2019; 11:2963-2976. PMC: 6489561. DOI: 10.2147/CMAR.S202664. View

5.
Zhang X, Tang W, Li R, He R, Gan T, Luo Y . Downregulation of microRNA-132 indicates progression in hepatocellular carcinoma. Exp Ther Med. 2016; 12(4):2095-2101. PMC: 5038555. DOI: 10.3892/etm.2016.3613. View